Establishing Edoxabans Role in Anticoagulation
Conclusion
Based on the 3 clinical trials, edoxaban appears to be a safe and effective factor Xa inhibitor in patients with a creatinine clearance of <95 mL/min. It will serve as an alternative anticoagulant for those with a preference for once-daily dosing and/or taking medications that interact with the CYP450 system.
Source: Journal of Pharmacy Practice - Category: Drugs & Pharmacology Authors: Guirguis, E., Brown, D., Grace, Y., Patel, D., Henningfield, S. Tags: Review Articles Source Type: research
More News: Atrial Fibrillation | Clinical Trials | Coumadin | Drugs & Pharmacology | Pradaxa | Stroke | Thrombosis | Warfarin